BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22014569)

  • 1. Resistance to EGFR-targeted therapy: a family affair.
    Vlacich G; Coffey RJ
    Cancer Cell; 2011 Oct; 20(4):423-5. PubMed ID: 22014569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
    Yonesaka K; Zejnullahu K; Okamoto I; Satoh T; Cappuzzo F; Souglakos J; Ercan D; Rogers A; Roncalli M; Takeda M; Fujisaka Y; Philips J; Shimizu T; Maenishi O; Cho Y; Sun J; Destro A; Taira K; Takeda K; Okabe T; Swanson J; Itoh H; Takada M; Lifshits E; Okuno K; Engelman JA; Shivdasani RA; Nishio K; Fukuoka M; Varella-Garcia M; Nakagawa K; Jänne PA
    Sci Transl Med; 2011 Sep; 3(99):99ra86. PubMed ID: 21900593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
    Mitsui K; Yonezawa M; Tatsuguchi A; Shinji S; Gudis K; Tanaka S; Fujimori S; Sakamoto C
    BMC Cancer; 2014 Nov; 14():863. PubMed ID: 25416285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.
    Yonesaka K; Tanaka K; Kitano M; Kawakami H; Hayashi H; Takeda M; Sakai K; Nishio K; Doi K; Nakagawa K
    Oncogenesis; 2019 Sep; 8(10):54. PubMed ID: 31570699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
    Maurer CA; Friess H; Kretschmann B; Zimmermann A; Stauffer A; Baer HU; Korc M; Büchler MW
    Hum Pathol; 1998 Aug; 29(8):771-7. PubMed ID: 9712416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery.
    Lee JC; Wang ST; Chow NH; Yang HB
    Eur J Cancer; 2002 May; 38(8):1065-71. PubMed ID: 12008194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer.
    Klupp F; Sass M; Bergmann F; Khajeh E; Ghamarnejad O; Hassenpflug M; Mehrabi A; Kulu Y
    Oncol Lett; 2021 Jun; 21(6):448. PubMed ID: 33868486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
    Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
    NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB2 and ErbB3 receptors mediate inhibition of calcium-dependent chloride secretion in colonic epithelial cells.
    Keely SJ; Barrett KE
    J Biol Chem; 1999 Nov; 274(47):33449-54. PubMed ID: 10559227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation.
    Feroz K; Williams E; Riese DJ
    Cell Signal; 2002 Sep; 14(9):793-8. PubMed ID: 12034361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.
    Frogne T; Benjaminsen RV; Sonne-Hansen K; Sorensen BS; Nexo E; Laenkholm AV; Rasmussen LM; Riese DJ; de Cremoux P; Stenvang J; Lykkesfeldt AE
    Breast Cancer Res Treat; 2009 Mar; 114(2):263-75. PubMed ID: 18409071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4.
    Fitzpatrick VD; Pisacane PI; Vandlen RL; Sliwkowski MX
    FEBS Lett; 1998 Jul; 431(1):102-6. PubMed ID: 9684874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z; Mei Y; Liu X; Zhou M
    Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
    Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
    Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
    Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.